Vanda Pharmaceuticals Inc.

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 16/01/2026 GMT			5-day change	1st Jan Change
7.470 ^USD	+0.27%		+1.91%	-15.31%

01-15	Vanda Pharmaceuticals Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-15-2026 09:00 AM
01-08	Wall Street Wavers Amid Trump's Defense Budget Plans, Driving Muted Premarket Action for US Equity Futures	MT

B. Riley Initiates Coverage on Vanda Pharmaceuticals With Buy Rating, $11 Price Target

Published on 11/05/2025 at 12:22 pm GMT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Vanda Pharmaceuticals Inc.

01-15	Vanda Pharmaceuticals Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-15-2026 09:00 AM
01-08	Wall Street Wavers Amid Trump's Defense Budget Plans, Driving Muted Premarket Action for US Equity Futures	MT
01-08	Vanda Pharmaceuticals Says FDA Rejects Hetlioz as Jet Lag Treatment	MT
01-08	Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ®? Supplemental New Drug Application for Jet Lag Disorder	CI
01-08	Vanda Shares Fall Premarket as FDA Again Rejects Hetlioz for Jet Lag	DJ
01-08	Top Premarket Decliners	MT
12-31	Wall Street ends 2025's final session lower but posts big annual gains	RE
12-31	Health Care Down on Mixed Drug Sales View -- Health Care Roundup	DJ
12-31	Wall Street ends year's final session lower but ends 2025 with big annual gains	RE
12-31	Top Midday Gainers	MT
12-31	Wall Street slips as tech continues to weigh, but nears annual gains	RE
12-31	Sector Update: Health Care Stocks Lean Lower Premarket Wednesday	MT
12-31	B. Riley Raises Price Target on Vanda Pharmaceuticals to $14 Form $11, Keeps Buy Rating	MT
12-31	Top Premarket Gainers	MT
12-31	Stocks Decline Pre-Bell Ahead of Final Trading Session of 2025	MT
12-31	US stock futures inch down in thin trading, but Wall Street eyes yearly gains	RE
12-31	Vanda Pharmaceuticals Says FDA Has Approved Nereus for Motion-Induced Vomiting; Shares Rise Pre-Bell	MT
12-31	Vanda Pharmaceuticals Announces FDA Approval of Nereus? (tradipitant) for the Prevention of Vomiting Induced by Motion	CI
12-31	Vanda Pharma Shares Rise After FDA Approves Motion Sickness Treatment	DJ
12-30	Vanda Pharmaceuticals announces FDA approval of Nereus (tradipitant)	RE
12-30	US FDA approves Vanda Pharmaceuticals' motion sickness drug	RE
12-26	Top Premarket Gainers	MT
12-15	Vanda Pharmaceuticals Rises on FDA Biologics License Application	DJ
12-15	Vanda Pharmaceuticals Inc. Announces Submission of Biologics License Application to FDA for Imsidolimab for Treatment of Generalized Pustular Psoriasis	CI
12-15	Vanda Pharmaceuticals Submits Biologics License Application to US FDA for Generalized Pustular Psoriasis Drug	MT

Chart Vanda Pharmaceuticals Inc.

Duration

Period

VNDA: Dynamic Chart

Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Companyâs commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Employees

368

Sector

Biotechnology & Medical Research

Calendar

02-10 - Q4 2025 Earnings Release (Projected)

More about the company